title: New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.
abstract: Key issues for prostate cancer patients are the detection of recurrent disease and the treatment of metastasized cancer. Early detection is a major challenge for all conventional imaging modalities. Furthermore, therapy of patients with hormone-resistant tumor lesions presents a major clinical challenge. Because the prostate-specific membrane antigen (PSMA) is frequently overexpressed in prostate cancer, several PSMA-targeting molecules are under development to detect and treat metastatic castration-resistant prostate cancer (mCRPC). mCRPC represents a situation where cure is no longer achievable and novel therapeutic approaches for palliation and increase of survival are needed. In this article, we discuss the recent development for noninvasive detection of recurrent disease and therapy of mCRPC with corresponding PSMA-targeted radioligands.
authors.affiliation: Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (dkfz), Heidelberg, Germany. uwe.haberkorn@med.uni-heidelberg.de.
authors.forename: Uwe
authors.initials: U
authors.lastname: Haberkorn
authors.affiliation: Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Eder
authors.affiliation: Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, Germany.
authors.forename: Klaus
authors.initials: K
authors.lastname: Kopka
authors.affiliation: Department of Radiopharmacy, Weill Cornell Medical College, New York, New York.
authors.forename: John W
authors.initials: JW
authors.lastname: Babich
authors.affiliation: Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. Division of Radiopharmaceutical Chemistry, German Cancer Research Center (dkfz), Heidelberg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Eisenhut
mesh_terms: D000954:Antigens, Surface / Q000378:metabolism*; D015415:Biomarkers; D003131:Combined Modality Therapy; D043425:Glutamate Carboxypeptidase II / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D008297:Male; D058990:Molecular Targeted Therapy; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000628:therapy; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D000954:Antigens, Surface; D015415:Biomarkers; D008024:Ligands; D019275:Radiopharmaceuticals; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II